AZD8529
Drugcomparison of different dosages of drug
Other names: AZD-8529
NCT Number: NCT02401022
To evaluate the efficacy and safety of AZD8529 for smoking cessation in female smokers.
Looking for future studies?
Notify Me18 year–75 year
Female
Interventional
Phase 2
Pharmacology Research Institute, Encino, California, United States
This is a 19-week, multi-center, randomized, Phase 2 clinical study comparing the efficacy of two different doses of AZD8529 (1.5 and 40 mg) in smoking cessation. Up to 2 weeks will be allowed for the Screening Period, followed by a 1-week, single-blind run-in period. At the end of Study Week 1 (on Study Day 8), medication compliance will be one of the factors used in a predictive enrichment strategy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
comparison of different dosages of drug
Other names: AZD-8529
Time frame: Weeks 10 - 13
The number of subjects in each treatment group who are smoking abstinence during the last 4 weeks of the treatment phase (weeks 10 through 13)
National Institute on Drug Abuse (NIDA)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03259360
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial DetailsNCT04560868
Behavior, Behavior, Smoking
Seattle, Washington, United States
View Trial DetailsNCT01691105
Behavior, Chemically-Induced Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT00507728
Behavior, Chemically-Induced Disorders
Houston, Texas, United States
View Trial Details